QSV Equity Investors’s Catalyst Pharmaceutical CPRX Stock Holding History

QSV Equity Investors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$840K	Sell	36,010 -17,476	-33%	-$389K	1.24%	40
2025 Q3	$1.05M	Buy	53,486 +48	+0.1%	+$987	1.08%	53
2025 Q2	$1.16M	Sell	53,438 -30,426	-36%	-$718K	1.21%	44
2025 Q1	$2.03M	Sell	83,864 -196	-0.2%	-$4.41K	2.11%	7
2024 Q4	$1.75M	Sell	84,060 -77	-0.1%	-$1.65K	1.69%	20
2024 Q3	$1.67M	Hold	84,137	–	–	1.57%	24
2024 Q2	$1.3M	Buy	+84,137	New	+$1.31M	1.36%	45

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

QSV Equity Investors's CPRX Position: Q4 2025 in Review

QSV Equity Investors reduced its Catalyst Pharmaceutical (CPRX) stake by 33% in Q4 2025, selling an estimated $389K and leaving 36,010 shares worth $840K. The position accounts for 1.24% of the portfolio, ranked #40.

QSV Equity Investors first reported a position in CPRX in Q2 2024 and has held it in 7 quarters since. The position peaked at $2.03M in Q1 2025. 373 funds tracked by Wall St. Rank hold CPRX as of Q4 2025.

QSV Equity Investors held 36,010 shares of Catalyst Pharmaceutical worth $840K as of Q4 2025.
QSV Equity Investors sold 17,476 Catalyst Pharmaceutical shares in Q4 2025, an estimated $389K.
Catalyst Pharmaceutical made up 1.24% of QSV Equity Investors's portfolio in Q4 2025, its #40 holding.
QSV Equity Investors first reported a position in Catalyst Pharmaceutical in Q2 2024 and has held it in 7 quarters since.
QSV Equity Investors's Catalyst Pharmaceutical position peaked at $2.03M in Q1 2025.
373 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2025.

Based on QSV Equity Investors's 13F filing for Q4 2025, filed 12 Feb 2026.